GSK4532990

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Liver Diseases, AlcoholicNon-alcoholic Fatty Liver DiseaseNonalcoholic Fatty Liver Disease

Phase 2

Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruitingNCT05583344

GlaxoSmithKlineNon-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease

Start: 2023-01-02End: 2026-09-18Updated: 2026-09-18

Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH

CompletedNCT06104319

GlaxoSmithKlineNon-alcoholic Fatty Liver Disease

Start: 2024-01-22End: 2025-09-23Updated: 2025-10-14

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

RecruitingNCT06613698

GlaxoSmithKlineLiver Diseases, Alcoholic

Start: 2024-09-27End: 2028-03-07Target: 393Updated: 2026-08-03